Navigation Links
Proteolix Names Matthew Ferguson to Newly-Created Position of Chief Financial Officer
Date:2/25/2008

SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Proteolix, Inc., a clinical-stage company engaged in the development of novel pharmaceutical therapies for the treatment of cancer and immunological conditions, announced that it has appointed Matthew Ferguson to the new position of Chief Financial Officer. Mr. Ferguson brings extensive experience arranging financing and managing rapid growth in both life sciences and technology companies.

"We are delighted to have Matt on board as a key member of the Proteolix management team," said Susan Molineaux, Ph.D., the Company's President and CEO. "His experience building teams and infrastructure in high-growth environments and securing financing in both the private and public markets will serve Proteolix well as we continue to advance our clinical and research programs."

Before joining Proteolix, Mr. Ferguson served as CFO at medical device maker FoxHollow Technologies, Inc. During his five-year tenure there, the company advanced its flagship technology for the treatment of peripheral arterial disease through development, FDA approval and commercial launch in the U.S. Mr. Ferguson led FoxHollow's 2004 initial public offering and played a significant role in the company's 2007 merger with ev3 Inc. Mr. Ferguson previously held a variety of financial management and business development positions at ChannelPoint, Inc. and Hewlett-Packard. Mr. Ferguson holds an M.B.A. from the University of California at Berkeley and M.S. and B.S. degrees in engineering from the University of Pennsylvania and Stanford University, respectively.

"The Proteolix opportunity is driven by an expert team, a large unmet clinical need and compelling early clinical results for carfilzomib," commented Mr. Ferguson. "I look forward to contributing my skills and experience towards our dual goals of improving the lives of patients and generating substantial returns for our shareholders."

About Proteolix

Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, and dedicated to discovering, developing and commercializing pharmaceutical therapies that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In Phase I clinical studies, the Company's lead product candidate, carfilzomib (PR-171), demonstrated single-agent activity in the treatment of relapsed and refractory multiple myeloma. Carfilzomib is currently in Phase II clinical studies to evaluate its safety and efficacy in multiple myeloma, lymphoma and solid tumor malignancies. Proteolix is also developing a pipeline of next-generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For more information, please visit the Company's website at http://www.proteolix.com.

Contact information:

Matthew Ferguson

investors@proteolix.com

650-266-2600


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting
2. Accident Fund Names General Agency Company its 2007 Agency of the Year
3. American Laser Centers Names Bill Van Huis as Chief Revenue Officer
4. Omron Healthcare Names New Chief Operating Officer Bob Kondraske
5. Birla Sun Life Insurance Names Quest Diagnostics its Exclusive Provider of Health Assessment Services in India
6. WeissComm Partners Names Tom Jones Managing Director to Deepen Global Product Communications Offering
7. Wyeth Consumer Healthcare Names New Head of Global R&D
8. Spectragenics Names Rpr Marketing Communications Agency of Record
9. Concentric Medical Names Kimberly Bridges as Vice President of Sales, Announces Receipt of $15 Million Growth Funding
10. Southern Research Institute Names Blaine Knight Vice President of Drug Discovery
11. CTG Names William D. McGuire a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor Foundation (IETF) will host ... tremor (ET). The seminar will take place on Saturday, Aug. 26 at the Embassy ... program will run from 9 a.m. to 12 p.m., with check-in beginning at 8 ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider of ... with WALLIX to expand its solution to help government contractors more quickly ... number of ways to address the authentication requirements within NIST SP800-171, but no ...
(Date:7/24/2017)... ... , ... Independence Blue Cross (Independence) and ... program, have signed a five-year agreement that will marshal resources from both organizations ... patients receive. The agreement also signifies Jefferson Health officially joining the Independence ...
(Date:7/24/2017)... California (PRWEB) , ... July 24, 2017 , ... ... of autologous fat (adipose) transfer systems announces the issuance of United States Patent ... patent) for its adipose filtration technology. The '398 and '324 patents cover ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... National Harbor, MD. This year's theme focuses on the new ISO/IEC 17025 standards. ... quality and integrity in testing and calibration will be changed. , As ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... 2017  Prime Therapeutics LLC (Prime) released this statement from ... today,s Institute for Clinical and Economic Review,s (ICER) public ... and value of abuse-deterrent formulations (ADF) of opioids. Prime was ... the meeting. "The ... to the use of abuse-deterrent formulations (ADF) in opioids in ...
(Date:7/15/2017)... 15, 2017 Enterin Inc., a Philadelphia ... disease (PD), today announced the completion of a $12.7 million ... Ventures III, as well as the participation of existing investors. ... to have the support of New Ventures III and our ... validation of the potential of our platform technology to transform ...
(Date:7/13/2017)... Medical Products, a leader in medical product innovation and global patient ... for hospice patient care. ... Centurion Medical Products ... pain management and emotional comfort are part of a hospice,s primary ... preventing unneeded emergency department admission due to severe fecal impaction. One ...
Breaking Medicine Technology: